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Summary
Objective: Depression and anxiety have been suggested to be associated with systemic inflam-
mation upregulation. However, results are not always consistent, which may be due to symptom
heterogeneity of depression and anxiety. There are some indications that associations with
inflammation are mainly driven by somatic symptoms of depression and anxiety. We therefore set
out to evaluate the differential association of somatic and cognitive symptoms of depression and
anxiety with inflammation, while adjusting for demographic, health related, and lifestyle related
variables.
Methods: We evaluated baseline data from 2861 participants from the Netherlands Study of
Depression and Anxiety (NESDA). The Inventory of Depressive Symptomatology and the Beck
Anxiety Inventory were used to assess depressive symptoms and anxiety symptoms. For both
scales somatic and cognitive symptoms scales were calculated. Baseline blood samples were
collected to determine high sensitivity C-Reactive Protein (CRP), interleukin (IL)-6, and Tumor
Necrosis Factor (TNF)-a. We used linear regression to analyze the associations adjusting for
demographics and health indicators and markers for an unhealthy lifestyle.
Results: After adjustment for sociodemographic and health indicators, depressive symptoms
were associated with higher levels of CRP, IL-6 and TNF-a. This association was mainly driven by
somatic symptoms. For anxiety, somatic symptoms were associated with higher levels of CRP, IL-6
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and TNF-a, whereas cognitive anxiety symptoms were associated with CRP (men only). Markers
of an unhealthy lifestyle explained the significant associations.
Conclusions: Especially somatic symptoms of depression and anxiety are associated with
inflammation. However, this association was mostly mediated through unhealthy lifestyles
among depressed and anxious individuals.
# 2013 Elsevier Ltd. All rights reserved.
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Depression and anxiety have been found to be prognostically
associated with various somatic conditions, including cardiac
disease (van Melle et al., 2004; Meijer et al., 2011), diabetes
(Stuart and Baune, 2012) and obesity (Luppino et al., 2010).
Low grade inflammation has been proposed as one of the
physiological links between both depression and anxiety and
adverse somatic outcomes (Howren et al., 2009; Stuart and
Baune, 2012). In the last decade a substantial amount of
research has been published on the depression—inflammation
relationship, in healthy (Dowlati et al., 2010) and cardiac
populations (Howren et al., 2009). Most of these studies
concern cross-sectional research, although some prospective
studies have been published (Gimeno et al., 2009; Stewart
et al., 2009; Duivis et al., 2011; Shaffer et al., 2011).
Despite the substantial amount of research published on
the depression—inflammation link, results are still conflicting
(Howren et al., 2009), with some studies reporting positive
associations (Bankier et al., 2009; Pizzi et al., 2010) and
others reporting negative findings (Whooley et al., 2007;
McGlory, 2009). Stewart et al. (2009) found that depressive
symptoms predicted an upregulation of interleukin 6 (IL-6)
after a 6-year follow-up in an otherwise healthy sample, but
inflammation did not predict depressive symptoms after 6
years. Another study reported that recurrent depressive
symptoms were associated with subsequent inflammation,
although this association was largely explained by lifestyle
behaviors (Duivis et al., 2011). In contrast, Gimeno et al.
(2009) found that after 11 years of follow-up, C-Reactive
Protein (CRP) and IL-6 were predictive of cognitive symptoms
of depression, but not vice versa. It is obvious from the
preceding that there is still considerable debate on whether
or not depression and inflammation are associated and which
factors contribute to this relationship. Meta-analyses (How-
ren et al., 2009; Dowlati et al., 2010) have also suggested
that substantial heterogeneity exists between studies which
could be attributed to the differences in the study samples
studied or the questionnaires used to determine depressive
symptoms.
Another possible explanation for inconsistencies in the
depression and inflammation link could be that most studies
report only on depression as a whole, whereas it might be
more suitable to pay attention to individual depressive
symptoms or dimension scores in relation to inflammation
(Elovainio et al., 2009). Based on the sickness behavior
theory (Dantzer et al., 2008), which argues that somatic
depressive-like symptoms such as fatigue, sleeping problems,
anorexia, and motor slowing can be the result of upregulated
inflammation levels, one could expect that possible associa-
tions between depression and inflammation are being missed
when taking depression as a whole into account. It could thus
be hypothesized that somatic symptoms show a strongerassociation with inflammation than cognitive symptoms,
and this should to be taken into account when investigating
the depression—inflammation relationship.
In the case of anxiety, less research is conducted on the
associations with inflammation. However, there is some evi-
dence suggesting that anxiety is associated with inflamma-
tion (Bankier et al., 2008; Hoge et al., 2009; von Kanel et al.,
2010) reporting small to large effect sizes. However, these
studies included relatively small samples (N < 120), which
could mask true effect sizes. As with depression, anxiety also
consists of somatic and cognitive symptoms. Although no
study has investigated the association of somatic and cogni-
tive anxiety symptoms with inflammation, one study found
that in women somatic symptoms of anxiety were associated
with an increased CHD risk, whereas more psychological
symptoms of anxiety were not (Nabi et al., 2010).
An additional possible explanation for prior conflicting
results of studies examining the link between anxiety/
depression and inflammation could be the possible mediating
effects of for instance lifestyle behaviors such as smoking,
physical activity, alcohol consumption and overweight. These
factors are not always included in multivariable analyses,
even though there is considerable evidence that markers of
an unhealthy lifestyle are associated with both depressive
(Wiesbeck et al., 2008; Patten et al., 2009; Luppino et al.,
2010) and anxiety symptoms (Mykletun et al., 2008; Strine
et al., 2008) as well as inflammation (Eckel et al., 2005;
Reichert et al., 2009; Dod et al., 2010). For instance, the
meta-analysis by Howren et al. (2009) found that effect sizes
were considerably smaller in studies that adjusted for body
mass index (BMI). Furthermore, a meta-analysis on depres-
sion and overweight reported that obesity can be the result of
depression, but also vice versa. Obesity has also been found
to be associated with higher levels of inflammation (O’Con-
nor et al., 2009). Finally, as the majority of studies has a
rather small sample size (N < 100), reported effect sizes can
be masked. In order to detect true significant associations
and to be able to adjust for important confounders or med-
iators, large sample sizes are needed.
We previously found in a large sample of 2415 participants
that depression diagnosis was associated with immune dys-
regulation in men with a late onset depression (Vogelzangs
et al., 2012), but we did not distinguish in symptom dimen-
sions of depression. We therefore set out to conduct second-
ary data-analysis in this same sample in which we will
thoroughly investigate the relationship between symptoms
profiles of depression and anxiety with inflammation. We
hypothesize that (1) mainly the somatic symptoms of depres-
sion and anxiety are associated with inflammation, and (2)
that the association between (somatic) depressive and anxi-
ety symptoms and inflammation will be partly explained by
markers of an unhealthy lifestyle such as smoking, alcohol
intake, BMI and physical inactivity.
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2.1. Design and participants
NESDA is an ongoing multi-center cohort study on the course
of depressive and anxiety disorders in the adult (18—65 years)
population. A total of 2981 participants were recruited from
the community (n = 564:19%), primary care (n = 1610: 54%)
and specialized mental health care (n = 807: 27%) including
controls and persons with a current or past depressive and/or
anxiety disorder for the baseline assessment from 2004 to
2007. Exclusion criteria were a primary clinical diagnosis of a
psychiatric disorder like psychotic disorder, obsessive com-
pulsive disorder, bipolar disorder or severe addiction disorder
and not being fluent in Dutch. A detailed description of the
NESDA study design and sampling procedures can be found
elsewhere (Penninx et al., 2008). Participants who had miss-
ing data on either CRP, IL-6, or TNF-a were excluded from the
analyses (n = 73). Additionally, participants who had not
returned the questionnaire or had too many missing values
on the Inventory of Depressive Symptomatology (IDS) (>6
missing items) or Beck Anxiety Inventory (BAI) (n = 47) (>8
missing items) were also excluded. This resulted in a total
sample of 2861 participants. This final sample consisted of
participant with a current or past depression and/or anxiety
diagnosis (N = 2231) and controls (N = 630). Excluded parti-
cipants were on average more often male (43% vs. 33%,
p = .02), current smokers (50% vs. 38.1%, p = .01) and more
often used tetracyclic antidepressants (4.2% vs. 1.7%,
p = .05). On average excluded participants attained less
years of education (mean = 11.5 vs. 12.2, p = .02). Their
mean scores on the IDS somatic scale were on average slightly
higher (9 vs. 7.9, p = .04). Total IDS scores, IDS cognitive scale
scores, BAI total scores, BAI somatic, and BAI cognitive scores
and inflammation levels were on average not different
between excluded and included participants ( p > .05).
The study protocol was approved by the Ethical Review Board
of each participating center, and all subjects provided a
written informed consent.
2.2. Depressive and anxiety symptoms
2.2.1. Depressive symptoms
The 30-item IDS self-report version was administered (Rush
et al., 1996). The IDS assesses the DSM-IV criterion symptom
domains for major depressive disorder, and in addition com-
monly associated symptoms (e.g. anxiety, irritability) and
symptoms relevant to melancholic and atypical features. The
questionnaire consists of 30 items, each with four answer
options (coded 0 through 3). The questionnaire uses a 7-day
timeframe for assessing symptom severity. The psychometric
properties of the IDS have shown to be acceptable; high
correlations were found between the IDS scores on the
Hamilton Depression Rating Scale and the Beck Depression
Inventory-I (www.ids-qids.org).
Principal Component Analysis performed by Wardenaar
et al. (2010) on the IDS revealed three dimensions, a mood
cognition dimension, an anxiety arousal dimension and a
sleep dimension. However, none of these subscales represent
a pure somatic or cognitive symptoms scale as based on the
symptoms from the DSM-IV (somatic: weight loss or gain,insomnia or hypersomnia, psychomotor agitation or retarda-
tion, and loss of energy of feeling tired; cognitive: anhedo-
nia, feeling depressed, feelings of worthlessness,
concentration problems, and recurrent thoughts of death).
The anxiety arousal dimension encompasses somatic symp-
toms such as psychomotor agitation and psychomotor slow-
ing. However, it also contains somatic complaints,
gastrointestinal complaints and panic/phobic symptoms
(Wardenaar et al., 2010), which are not a part of sickness
behavior. We therefore created a pure somatic and a pure
cognitive symptom scale based on DSM-IV criteria and pre-
vious research on somatic and cognitive depression symptoms
(de Jonge et al., 2007; Hoen et al., 2010) (Table 1). Both the
somatic and the cognitive subscale consisted of 10 items
derived from the IDS (Table 1). Because the sleep symptoms
were over represented (4 items; falling asleep, sleep during
the night, waking up early, and sleeping too much), we
created a variable combining the four sleep items by taking
the mean score of all four items. This resulted in Cronbach’s
a = 0.69 for the somatic symptom dimension and Cronbach’s
a = 0.89 for the cognitive symptom dimension.
2.2.2. Anxiety symptoms
We used the 21-item BAI (Beck et al., 1988) to measure
symptoms of generalized anxiety and panic symptoms.
Respondents are asked to rate how much they have been
bothered by each symptom over the past week on a 4-point
scale, ranging from 0 (not at all) to 3 (severely, I could barely
stand it). The BAI is scored by summing the ratings for all of the
21 symptoms to obtain a total score that can range from 0 to 63.
The internal and test—retest reliability and validity of the BAI
are well-established (Beck et al., 1988; Osman et al., 2002)
Previous research has shown that factorial validity analy-
sis revealed that the BAI consists of two subscales accounting
for 84% of the variance i.e. a somatic subscale and a sub-
jective — or cognitive — subscale (Kabacoff et al., 1997). The
somatic subscale consists of 14 items (Cronbach’s
alpha = .90) such as numbness or tingling, feeling hot, diffi-
culty in breathing, and heart pounding and the cognitive
subscale consists of 7 items (Cronbach’s alpha = .88) such as
fear of losing control, fear of dying, and being terrified or
afraid (Table 1). These two subscales still discriminate ade-
quately between patients with and without an anxiety dis-
order (Kabacoff et al., 1997).
2.3. Inflammatory markers
As described before (Vogelzangs et al., 2012) markers of
inflammation were assessed at the baseline NESDA assess-
ment and include high sensitivity C-Reactive Protein (CRP),
interleukin-6 (IL-6), and Tumor Necrosis Factor (TNF)-a which
have been found to be associated with depressive symptoms
and major depression in earlier studies (Howren et al., 2009;
Dowlati et al., 2010; Vogelzangs et al., 2012). CRP is a non-
specific acute phase protein synthesized in the liver in
response to amongst others stimulation from IL-6 and IL-6
is a pro-inflammatory cytokine secreted by activated macro-
phages. TNF-a is the prototypic ligand of the TNF superfamily
and plays a central role in inflammation. After an overnight
fast, 50 ml blood was drawn which was immediately trans-
ferred to a local laboratory and kept frozen at 80 8C. High-
sensitivity plasma levels of CRP were measured in duplicate
Table 1 Overview of the somatic and cognitive symptoms of
depression (IDS) and anxiety (BAI) as measured with the items
of the Inventory of Depressive Symptoms.
Somatic symptoms Cognitive symptoms
(a) Depressive symptoms (IDS)
Falling asleepa Feeling sad
Sleep during the nighta Feeling irritable
Waking up to earlya The quality of mood
Sleeping too mucha Concentration/
decision making
Decreased or increased
appetite
View of the self
Decreased or increased
weight
Thoughts of death
or suicide
Energy level General interest
Feeling slowed down Capacity for pleasure or
enjoyment (excluding sex)
Feeling restless Interest in sex
Leaden paralysis/physical
energy
Interpersonal sensitivity
(b) Anxiety symptoms (BAI)
Numbness or tingling Unable to relax
Feeling hot Fear of worst happening
Wobbliness in legs Terrified or afraid
Dizzy or light-headed Nervous
Heart pounding/racing Fear of losing control
Unsteady Fear of dying
Feeling of choking Scared
Hands trembling
Shaky/unsteady
Difficulty in breathing
Indigestion
Faint/light-headed
Face flushed
Hot/cold sweats
IDS, Inventory of Depressive Symptomatology; BAI, Beck Anxiety
Inventory.
a Merged to one variable reflecting sleeping problems.
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anti-CRP antibodies (Dako, Glostrup, Denmark). The CRP assay
was standardized against the CRM 470 reference agent. The
lower detection limit of CRP is 0.1 mg/l and the sensitivity is
0.05 mg/l. Intra- and inter-assay coefficients of variation were
5% and 10%, respectively. Plasma IL-6 levels were measured in
duplicate by a high sensitivity enzyme-linked immunosorbent
assay (PeliKine CompactTM ELISA, Sanquin, Amsterdam). The
IL-6 assay was standardized against a recombinant human IL-6
standard. The lower detection limit of IL-6 is 0.35 pg/ml and
the sensitivity 0.10 pg/ml. Intra- and inter-assay coefficients
of variation were 8% and 12%, respectively. Plasma TNF-a
levels were assayed in duplicate at Good Biomarker Science,
Leiden, The Netherlands, using a high-sensitivity solid phase
ELISA (Quantikine1 HS Human TNF-a Immunoassay, R&D sys-
tems Inc, Minneapolis, MN, United States). The TNF-a assay
was calibrated against a highly purified Escherichia coli-
expressed recombinant human TNF-a. The lower detection
limit of TNF-a is 0.10 pg/ml and the sensitivity 0.11 pg/ml.
Intra- and inter-assay coefficients of variation were 10% and15%, respectively. The distribution of CRP, IL-6, and TNF-a was
tested for normality using skewness and kurtosis. These tests
revealed that all three markers were not normally distributed.
Values were therefore log transformed, which resulted in
normal distributed variables.
Blood was collected between 0800 h and 0900 h in the
morning of the baseline assessment. On average, blood was
collected 5 days after the IDS and BAI were filled out (SD = 23
days).
2.4. Covariates
Sociodemographic factors included age, sex, and years of
education. In addition, some health factors were assessed. In
order to ascertain the presence of cardiovascular disease
(CVD), self-reports and medication use were used (based on
drug container inspection and World Health Organization
Anatomic Therapeutic Chemical (ATC) coding; see Vogelzangs
et al. (2010) for a detailed description). Presence of diabetes
was based on fasting plasma glucose level  7.0 mmol/l or
use of anti-diabetic medication (ATC code A10).
Participants were asked to bring the containers of the
medication used during the month prior to the interview, so
the research assistant could copy medicine names. We used
the ATC classification (WHO, 2008) to classify frequently used
(>50% of all days in past month) medication (Table 2). We
included use of systemic anti-inflammatory medication
(M01A, M01B, A07EB, and A07EC) and statin use (C10AA,
C10B) as covariates. For antidepressant medication, selec-
tive serotonin reuptake inhibitors (SSRI; N06AB), serotonin—
norepinephrine reuptake inhibitors (SNRI; SNRI; N06AX16 and
N06AX21), tricyclic antidepressants (TCA; N06AA), and tet-
racyclic antidepressants (TeCA; N06AX03, N06AX05 and
N06AX11) were included as covariates.
Markers of an unhealthy lifestyle were considered as cov-
ariates, because they have been linked to both psychopathol-
ogy and inflammation. Smoking status was categorized as
nonsmoker, former, and current smoker and alcohol intake
was measured with the Alcohol Use Disorders Identification
Test (Saunders et al., 1993; Boschloo et al., 2010) and defined
as <1 glass per week, 1—14 glasses per week and >14 glasses
per week. Body Mass Index (BMI) was determined as measured
weight in kilograms divided by the square of the measured
height in meters. Physical activity was assessed using the
International Physical Activity Questionnaire (Craig et al.,
2003). This 7-item instrument assesses the amount of time
spent on vigorous, moderate, walking and sitting activities
over the last 7 days. For instance, participants have to indicate
on how many days during the last seven days they participated
in heavy physical activities such as lifting, aerobics, or digging
(during at least 10 min) and how many hours and/or minutes
they spent on these activities on average. These scores are
then used to calculate the total Metabolic Equivalent Total
(MET)-minutes per week (ratio of energy expenditure during
activity compared to rest times the number of minutes per-
forming the activity) (www.ipaq.ski.se).
2.5. Statistical analyses
Characteristics of the participants were compared across
men and women using independent t-tests for continuous
Table 2 Descriptives for the total sample, and for men and women separately.
Total Men Women
N = 2861 N = 950 N = 1911
N or mean % or SD N or mean % or SD N or mean % or SD p*
Demographics + health
Age 41.9 13.0 43.6 12.8 41.1 13.1 <.001
Education (years) 12.2 3.3 12.2 3.3 12.2 3.3 .685
Health
Diabetes 138 5% 75 8% 63 3% <.001
Cardiovasculair disease 163 6% 91 10% 72 4% <.001
Medication use
Anti-inflammatory drugs 129 5% 38 4% 91 5% .355
Statins 191 7% 99 10% 92 5% <.001
Antidepressants 697 24% 224 24% 473 25% .491
SSRI 481 17% 150 16% 331 17% .302
SNRI 110 4% 40 4% 70 4% .473
TCA 77 3% 21 2% 56 3% .263
TeCA 50 2% 24 3% 26 1% .025
Markers of unhealthy lifestyle
Smoking
No 802 28% 229 24% 573 30% .003
Former 970 34% 331 35% 639 33%
Current 1089 38% 390 41% 699 37%
Alcohol intake
<1 glass per week 923 32% 207 22% 716 37% <.001
1—14 glasses per week 1608 56% 635 67% 973 51%
>14 glasses per week 330 12% 108 11% 222 12%
BMI 25.6 4.9 26.2 4.5 25.3 5.2 <.001
Physical activity (in MET-minutes per week) 3678 3028 3728 3296 3652 2887 .544
Depression and anxiety
IDS total score 21.4 14.1 20.8 14.7 21.8 13.8 .074
IDS somatic score 7.9 5.1 7.5 5.4 8.1 5.0 .004
IDS cognitive score 7.7 6.4 7.6 6.6 7.7 6.3 .725
BAI total score 12.0 10.6 11.2 10.6 12.5 10.6 .002
BAI somatic score 7.3 6.9 6.7 6.9 7.5 6.8 .004
BAI cognitive score 4.8 4.5 4.4 4.4 4.9 4.6 .005
Inflammatory markers
C-Reactive Protein (mg/L) 0.25 1.24 0.11 1.21 0.32 1.25 <.001
Interleukin 6 (pg/L) 0.28 0.98 0.22 0.93 0.31 1.00 .023
Tumor Necrosis Factor-alpha (pg/L) 0.18 0.63 0.17 0.55 0.19 0.66 .382
BMI, body mass index; IDS, Inventory of Depressive Symptomatology; BAI, Beck Anxiety Inventory.
* Calulated with t-tests, chi-square tests, ANOVA.
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and categorical variables, and Mann—Whitney U for the
inflammatory markers.
The relationships of depressive symptoms and anxiety
symptoms with inflammation were analyzed using linear
regression analyses. Total depressive symptoms score,
somatic symptoms of depression, cognitive symptoms of
depression, total anxiety symptoms score, somatic symptoms
of anxiety, and cognitive symptoms of anxiety were sepa-
rately analyzed as predictors of CRP, IL-6, and TNF-a. In total,
24 models were analyzed. First unadjusted regression ana-
lyses were conducted. Next, a demographics and health
model was evaluated, adjusting for age, sex, education level,
presence of CVD and diabetes, anti-inflammatory medication
and statin use. Secondly, when significant correlationsbetween inflammatory markers and specific antidepressant
medications were present, analyses were further adjusted
for those specific medications. We chose to restrict analyses
to these medications, because adjusting for all antidepres-
sant medication possibly leads to overadjusting for those
participants with the most severe depressive and anxiety
symptoms. CRP was significantly negatively correlated with
SSRI, and positively correlated with TCA, and TeCA use
( p < .05). TNF-a was positively correlated with TCA
( p < .01). There were no significant correlations between
IL-6 and antidepressant medication use. Because of possible
mediating effects of markers of an unhealthy lifestyle
(O’Connor et al., 2009) smoking, alcohol intake, BMI, and
physical activity were added in a final step to the previous
models. To further investigate the mediating effects of
Table 3 Linear regression analyses for depressive symptoms (IDS) and inflammation.
CRP IL-6 TNF-a
b p b p b p
IDS total score Men Total sample Total sample
Unadjusted .162 <.001 .074 <.001 .061 .001
Demographics + health .104 .001 .046 .015 .039 .042
Antidepressant medication .092 .005 .046 .015 .035 .068
Lifestyle .043 .159 .010 .586 .022 .273
IDS total score Women
Unadjusted .057 .012
Demographics + health .015 .517
Antidepressant medication .002 .929
Lifestyle .038 .09
IDS somatic Total sample Total sample Total sample
Unadjusted .124 <.001 .088 <.001 .070 <.001
Demographics + health .078 <.001 .054 .005 .045 .018
Antidepressant medication .067 <.001 .054 .005 .042 .028
Lifestyle .022 .231 .017 .366 .028 .155
IDS cognitive Total sample Total sample Total sample
Unadjusted .054 .004 .046 .015 .050 .008
Demographics + health .021 .268 .028 .128 .035 .067
Antidepressant medication .004 .830 .028 .128 .031 .099
Lifestyle .028 .116 .001 .954 .020 .303
b reflects standardized coefficients.
Demographics + health: age, sex, years of education, presence of cardiovascular disease and diabetes, anti-inflammatory medication use,
and statin use.
Antidepressant medication: Demographics + health + antidepressant medication; only adjusted for antidepressant medication use when
significant correlation was present with inflammatory marker. CRP analyses were adjusted for selective serotonin reuptake inhibitor
( p = .04), tricyclic antidepressants ( p < .01), and tetracyclic antidepressants ( p < .01). TNF-a analyses were adjusted for tricyclic
antidepressants ( p < .01). There were no significant correlations between IL-6 and antidepressant medication use, and therefore these
analyses were not further adjusted.
Lifestyle: Demographics + health + antidepressant medication + smoking, alcohol intake, BMI, and physical activity.
IDS, Inventory of Depressive Symptomatology; CRP, C-Reactive Protein; IL-6, interleukin 6; TNF-a, Tumor Necrosis Factor-alpha.
Bold faced: p  .05.
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conducted using the indirect method by Preacher and Hayes
(Preacher and Hayes, 2008). This method estimates total,
direct, and indirect unstandardized effects of the predictor
(IDS or BAI [sub]scales) on the outcome (inflammatory bio-
marker) through the mediator variables smoking, alcohol
intake, BMI, and physical activity, while controlling for cov-
ariates (Preacher and Hayes, 2008). Mediation analyses will
only be conducted for significant associations found with
linear regression analyses after adjustment for demo-
graphics, health, and medication use. Furthermore, media-
tion analyses will be adjusted for demographics, health, and
medication use.
Since Vogelzangs et al. (2012) found sex differences in the
association between depression and inflammation, we tested
for the presence of interaction effects for sex and included
the following interaction terms for sex (sex*IDS total, sex*IDS
somatic, sex*IDS cognitive, sex*BAI total, sex*BAI somatic,
sex*BAI cognitive) in respective models. When the interac-
tion effect was found significant, regression analyses were
repeated stratified for sex.3. Results
3.1. Baseline characteristics
Table 2 shows the descriptive characteristics of the total
study sample (N = 2861) of which 950 were male (33.2%). Men
were significantly older than women (mean age 43.6 vs. 41.1,
p < .001), were more often smoker (41% vs. 37%, p = .003),
and had higher levels of BMI (mean BMI 26.2 vs. 25.3,
p < .001). Women more often used <1 glass of alcohol per
week (37% vs. 22%) and men more often used 1—14 glasses of
alcohol per week (67% vs. 51%) ( p < .001). Furthermore,
cardiovascular disease ( p < .001) and diabetes ( p < .001)
were more present in men and men used statins ( p < .001)
and TeCA ( p = .025) more often than women. Men had higher
IDS somatic symptoms scores than women ( p = .004),
whereas women had higher BAI total scores ( p = .002), BAI
somatic ( p = .004), and BAI cognitive scores ( p = .005).
Finally, women had on average higher of CRP ( p < .001)
and lower levels of IL-6 ( p = .023) (Table 2).
Table 4 Linear regression analyses for anxiety symptoms (BAI) and inflammation.
CRP IL-6 TNF-a
b p b p b p
BAI total score Men Total sample Total sample
Unadjusted .147 <.001 .059 .002 .057 .002
Demographics + health .106 .001 .034 .070 .035 .067
Antidepressant medication .094 .003 .034 .070 .031 .107
Lifestyle .038 .203 .001 .948 .021 .283
BAI total score Women
Unadjusted .055 .015
Demographics + health .010 .682
Antidepressant medication .004 .856
Lifestyle .022 .327
BAI somatic Men Total sample Total sample
Unadjusted .165 <.001 .080 <.001 .064 .001
Demographics + health .116 <.001 .050 .008 .038 .046
Antidepressant medication .105 .001 .050 .008 .034 .080
Lifestyle .045 .134 .015 .425 .023 .246
BAI somatic Women
Unadjusted .073 .002
Demographics + health .026 .272
Antidepressant medication .012 .627
Lifestyle .012 .601
BAI cognitive Men Total sample Total sample
Unadjusted .095 .003 .017 .356 .037 .050
Demographics + health .073 .018 .005 .774 .024 .208
Antidepressant medication .059 .060 .005 .774 .021 .266
Lifestyle .020 .486 .019 .305 .014 .454
BAI cognitive Women
Unadjusted .020 .372
Demographics + health .015 .503
Antidepressant medication .026 .270
Lifestyle .031 .150
b reflects standardized coefficients.
Demographics + health: age, sex, years of education, presence of cardiovascular disease and diabetes, anti-inflammatory medication use,
and statin use.
Antidepressant medication: Demographics + health + antidepressant medication; only adjusted for antidepressant medication use when
significant correlation was present with inflammatory marker. CRP analyses were adjusted for selective serotonin reuptake inhibitor
( p = .04), tricyclic antidepressants ( p < .01), and tetracyclic antidepressants ( p < .01). TNF-a analyses were adjusted for tricyclic
antidepressants ( p < .01). There were no significant correlations between IL-6 and antidepressant medication use, and therefore these
analyses were not further adjusted.
Lifestyle: Demographics + health + antidepressant medication + smoking, alcohol intake, BMI, and physical activity.
BAI, Beck Anxiety Inventory; CRP, C-Reactive Protein; IL-6, interleukin 6; TNF-a, Tumor Necrosis Factor-alpha.
Bold faced: p  .05.
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Table 3 shows results of the linear regression analyses
associating depressive symptoms with inflammation. Sig-
nificant sex interactions were found with depressive symp-
toms (IDS total score) predicting CRP (IDS: b = .192,
p = .003; sex: b = .156, p  .001; IDS*sex b = .164,
p = .02), which lead us to stratify the concerning analyses
for sex. Considering somatic symptoms and cognitive symp-
toms of depression, there were no significant interactions
with sex for any of the markers (all p values for sex
interactions > .06).3.2.1. IDS total score
In line with our previous findings (Vogelzangs et al., 2012),
unadjusted analyses showed a positive significant association
between IDS total score and CRP (men: b = .192, p = .003;
women b = .057, p = .012), IL-6 (b = .074, p < .001), and TNF-
a (b = .061, p = .001). Demographic and health adjusted
regression analyses revealed a positive significant association
between IDS total score and CRP for (men only: b = .104,
p < .001), IL-6 (b = .046, p = .015) and TNF-a (b = .039,
p = .042). Additional adjustment for antidepressant use that
showed an association with inflammatory markers, only
had an effect on the association between IDS total score
Table 5 Summary of Preacher and Hayes mediator model analyses (1000 bootstraps) between IDS/BAI (IV), and inflammation
(DV).a
Independent
variables (IV)
Mediating v
ariables (M)
Dependent
variable (DV)
Effect of IV
on M (a)
Effect of
M on DV (b)
Direct effect
(c0)
Total effect
(c)
Effect p Effect p
IDS total score (men only) CRP .005 .061 .008 .005
BMI CRP .015 .091 **
Physical activity CRP 17.77 * .000
Smoking CRP .004 * .260 **
Alcohol use CRP .004 ** .040
IDS total score IL-6 .002 .260 .003 .015
BMI IL-6 .025 ** .038 **
Physical activity IL-6 19.73 ** .000
Smoking IL-6 .005 ** .088 **
Alcohol use IL-6 .004 ** .042
IDS somatic score CRP .005 .262 .015 .002
BMI CRP .080 ** .103 **
Physical activity CRP 25.90 * .000
Smoking CRP .010 ** .108 **
Alcohol use CRP .007 ** .031
IDS somatic score IL-6 .005 .150 .010 .004
BMI IL-6 .088 ** .039 **
Physical activity IL-6 34.081 ** .000
Smoking IL-6 .012 ** .088 **
Alcohol use IL-6 .009 ** .042
IDS somatic score TNF-a .004 .082 .005 .027
BMI TNF-a .086 ** .010 **
Physical activity TNF-a 32.37 ** .000
Smoking TNF-a .012 ** .017
Alcohol use TNF-a .009 ** .048
BAI total score (men only) CRP .006 .089 .011 .003
BMI CRP .036 ** .090 **
Physical activity CRP 24.90 * .000
Smoking CRP .004 .263 **
Alcohol use CRP .003 .046
BAI somatic score (men only) CRP .010 .047 .018 .001
BMI CRP .061 ** .090 **
Physical activity CRP 24.40 .000
Smoking CRP .007 .262 **
Alcohol use CRP .004 .045
BAI somatic score IL-6 .004 .177 .007 .009
BMI IL-6 .045 ** .038 **
Physical activity IL-6 25.50 ** .000
Smoking IL-6 .014 ** .087 **
Alcohol use IL-6 .006 ** .043
IDS, Inventory of Depressive Symptomatology; BAI, Beck Anxiety Inventory.
a Adjusted for age, gender, years of education, presence of cardiovascular disease and diabetes, anti-inflammatory medication use, statin
use, and anti-depressant medication use.
* p < .05.
** p < .001.
1580 H.E. Duivis et al.and TNF-a (adjusted for TCA; b = .035, p = .068). Final addi-
tional adjustment for lifestyle made the remaining associa-
tions non-significant for all three markers ( p > .15).
Mediation analyses were conducted for IDS total score and
CRP (men only) and IL-6 which both had a significant totaleffect (c path) (Table 5). The direct effect was not significant
for IDS total score and CRP and IL-6 (c0 path) (Table 5) which
suggests a mediation effect of the mediator variables. Sig-
nificant associations were found for IDS total score and higher
BMI, smoking, physical activity, and alcohol use (a path)
Depressive and anxiety symptoms & inflammation 1581(Table 5). Both a higher BMI and smoking were significantly
associated with CRP and IL-6 (path b) (Table 5). In sum, these
analyses suggest an overall effect of IDS on CRP and IL-6, with
BMI and smoking largely mediating this effect.
3.2.2. IDS somatic symptoms
Somatic symptoms of depression were significantly asso-
ciated with all three markers in an unadjusted model
(CRP: b = .124 p < .001; IL-6 b = .088, p < .001, TNF-a:
b = .070, p < .001). All associations remained significant
after adjustment for demographics and health (CRP:
b = .078, p < .001; IL-6: b = .054, p  .001, and TNF-a:
b = .045, p = .018). Final adjustment for lifestyle made the
association non-significant for CRP, IL-6, and TNF-a.
Mediation analyses showed a direct association between
somatic symptoms of depression and BMI, physical activity,
smoking, and alcohol use (a path) and a direct association
between BMI and smoking status and CRP and IL-6 (b path)
(Table 5). Furthermore, a direct association was found for BMI
and TNF-a (b path) (Table 5). Although total effects were
found for somatic symptoms of depression and all three
markers (c path), no significant direct effects were found
for somatic symptoms of depression and any of the markers
(c0 path) (Table 5). Taken together, these results imply an
overall effect of IDS somatic symptoms on CRP, IL-6, and TNF-
a with BMI and smoking mediating this effect.
3.2.3. IDS cognitive symptoms
Cognitive symptoms of depression were significantly asso-
ciated with CRP (b = .054, p = .004) IL-6 (b = .046, p = .015),
and TNF-a (b = .050, p = .008). After adjustment for demo-
graphics and health, all associations diminished to non-sig-
nificance.
3.3. Symptoms of anxiety and inflammation
Table 4 shows the results of the linear regression analyses
associating anxiety symptoms with inflammation. Significant
interactions were found for sex and BAI total score when
analyzing CRP (BAI total score: b = .192, p = .004; sex:
b = .140, p < .001; BAI*sex: b = .166, p = .020), sex and
somatic symptoms of anxiety (BAI somatic b = 203,
p = .003: sex: b = .135, p < .001; BAI somatic* sex:
b = .162, p = .021), and sex and cognitive symptoms of
anxiety (BAI cognitive: b = .145, p = .036; sex: b = .132,
p < .001; BAI cognitive*sex: b = .141, p = .051). These
results will therefore be presented stratified for sex. No
sex-interactions were found for IL-6 or TNF-a (all p > .05).
3.3.1. BAI total score
BAI total score was significantly associated with CRP (men:
b = .147, p < .001; women: b = .055, p = .015), IL-6 (b = .059,
p = .002), and TNF-a (b = .057, p = .002). Adjusting for demo-
graphics and health only yielded significant association
between BAI somatic symptoms and CRP in men (b = .106,
p < .001). Final adjustment for lifestyle diminished the asso-
ciation to non-significance (b = .038, p = .203).
Additional mediation analyses showed a direct effect of
BAI total score on BMI and physical activity (a path) and a
direct effect of BMI and smoking status on CRP (b path) (Table
5). Significant total effects were found for BAI total score andCRP (c path) (Table 5). No significant direct effects were
found for BAI total score and CRP (c0 path) (Table 5), which
suggests an overall effect of BAI total score on CRP levels with
BMI mediating this effect.
3.3.2. BAI somatic symptoms
Unadjusted regression analyses showed that somatic symp-
toms of anxiety were significantly associated with CRP (men:
b = .165, p < .001; women: b = .073, p = .002), IL-6 (b = .080,
p < .001), and TNF-a (b = .064, p = .001). The associations
remained significant after adjustment for demographics and
health (CRP men only: b = .116, p < .001; IL-6: b = .050,
p = .008; TNF-a: b = .038, p = .046). Additional adjustments
for antidepressant use diminished the association between
somatic symptoms and TNF-a (adjusted for TCA; b = .034,
p = .080). Finally, adjusting for lifestyle resulted in dimin-
ished, non-significant associations for somatic (b = .045,
p = .134) symptoms of anxiety and CRP and for somatic
anxiety symptoms and IL-6 (b = .015, p = .425).
Mediation analyses showed a direct effect of somatic
symptoms of anxiety on BMI, smoking status, physical activity
and alcohol use (a path) (Table 5). BMI and smoking status
showed a direct effect on CRP and IL-6 (b path) (Table 5).
Significant total effects were found for somatic symptoms of
anxiety and CRP and IL-6 (c path) (Table 5). Significant direct
effects were only found for somatic symptoms of anxiety and
CRP (c0 path) (Table 5). This suggests an overall effect of
somatic symptoms of anxiety on CRP and IL-6 levels with BMI
and smoking largely mediating this effect, although for CRP
some non-mediated association remained.
3.3.3. BAI cognitive symptoms
Unadjusted regression analyses revealed significant associa-
tion between CRP (men only b = .095, p = .003) and TNF-a
(b = .037, p = .050). After adjusting for demographics and
health cognitive symptoms of anxiety remained associated
with CRP (men) only (b = .073, p = .018). No associations
were found between cognitive anxiety symptoms and IL-6
or TNF-a. Further adjustment for antidepressant use dimin-
ished the association between cognitive symptoms and CRP
(adjusted for SSRI, TCA, and TeCA; b = .059, p = .060).
4. Discussion
This study shows that higher depressive symptoms were
associated with higher inflammatory levels of CRP, IL-6,
and TNF-a, but this was mainly driven by the somatic —
and not the cognitive — symptoms of depression. This sup-
ports the hypothesis that somatic symptoms and cognitive
symptoms of depression are differently associated with
inflammation. Regarding symptoms of anxiety, total, somatic
and cognitive symptoms were all similarly associated with
higher CRP (men only). IL-6 and TNF-a levels were only
associated with somatic symptoms of anxiety. For all signifi-
cant associations, lifestyle played an important role, with
BMI explaining most of the relationship.
The results from this study support the hypothesis that
somatic and cognitive symptoms are differently associated
with inflammation suggesting that the association between
depression and inflammation is mainly driven by somatic
symptoms. This is in concordance with some previous
1582 H.E. Duivis et al.findings. Elovainio et al. (2009) found that somatic symptoms
were more strongly associated with CRP in men than in
women, even after full adjustment for covariates. In contrast
to our findings, Elovainio and colleagues found significant
associations between cognitive symptoms and CRP. However,
these were unadjusted or for every covariate separately
adjusted analyses. Contradictory findings have also been
reported. Kupper et al. (2012) found that both somatic
and cognitive symptoms were cross-sectionally associated
with inflammation in a sample of heart failure patients.
Furthermore, cognitive symptoms of depression were asso-
ciated with subsequent inflammation, whereas change in
somatic symptoms over a 12 month period were associated
with inflammation (Kupper et al., 2012). One possible expla-
nation for the differences in the cross-sectional results
between these studies could be that our study and Elovainio
and colleagues’ study consisted of somatic healthy partici-
pants, whereas Kupper and colleagues used a sample of heart
failure patients, whom probably have higher levels of inflam-
mation to begin with due to their disease status. Further-
more, the heart failure sample is on average older, possibly
affecting cognitive functions comparable to cognitive symp-
toms of depression (i.e. concentration).
Interestingly, in a recent review on somatic symptoms of
depression as a predictor of cardiac disease, Carney and
Freedland (2012) describe that somatic symptoms are more
often residual symptoms of a depression in remission and are
also risk factors for chronic or recurrent depression. Previous
research has shown that especially recurrent depressive
symptoms are associated with future inflammation in stable
coronary heart disease patients (Duivis et al., 2011, 2012). It
could be that somatic symptoms reported on in this study are
a reflection of residual symptoms of depression and a risk
factor for future depressive symptoms or depression, with a
possible role for inflammation.
Comparable to the results from Elovainio et al. (2009) and
Bremmer et al. (2008), we also found sex differences in the
associations between depressive symptoms and anxiety
symptoms with inflammation. It has been suggested that
differences between men and women in the association
between depression/anxiety and inflammation are the
results of hormonal differences (Jilma et al., 1997; Cushman
et al., 1999). However, in our previous study on depression
diagnosis and inflammation, hormonal status did not affect
the association between depression and inflammation.
Another potential explanation could come from non-biologi-
cal pathways. For example, it has been suggested that
women have a greater risk for depression than man as a
result of insufficient support and stressful life events (Macie-
jewski et al., 2001; Kendler et al., 2005). Gender differences
were only present for CRP, which is a more general marker for
inflammation than IL-6 and TNF-a are. Possibly, these psy-
chosocial factors only have less impact on other, more spe-
cific markers of inflammation.
As was found in previous research (Hamer et al., 2009;
Stewart et al., 2009; Duivis et al., 2011), this study shows
that lifestyle, and mainly BMI, explained a significant part of
the association between depressive symptoms and inflamma-
tion. Obesity has been found to be associated with depression
(de Wit et al., 2010; Luppino et al., 2010). A meta-analysis on
the prospective association between overweight and depres-
sion showed that the relationship is bi-directional, in otherwords, depression predicts obesity and obesity is a risk factor
for depression (Luppino et al., 2010). Obesity has also been
found to be associated with higher levels of inflammation
(Miller et al., 2003; O’Connor et al., 2009). Research suggests
that adipose tissue produces IL-6 and TNF-a (Miller et al.,
2003; O’Connor et al., 2009) and this is therefore a plausible
link between depressive symptoms and inflammation (Miller
et al., 2003). Furthermore, Dod et al. (2010) found that
intervening in markers of an unhealthy lifestyle, by changing
food intake and enhancing moderate exercise, had significant
effects on lowering inflammation levels after 12 weeks. As
higher levels of inflammation are found to be associated with
adverse health outcomes such as cardiac risk factors (Toprak
et al., 2011) and diabetes (Stuart and Baune, 2012), promot-
ing weight loss in people with depressive symptoms could
have beneficial effects on levels of inflammation and possibly
future health status.
Regarding anxiety and inflammation, we found a signifi-
cant association between total anxiety symptoms and CRP
(men only) whereas somatic symptoms were associated with
CRP (men only), IL-6, and TNF-a. These associations also
diminished after lifestyle differences were considered. In
line with our findings on total symptoms of anxiety, previous
studies also reported on a positive association between
anxiety and inflammation (Pitsavos et al., 2006; Liukkonen
et al., 2011). Liukkonen et al. (2011) found that men report-
ing anxiety symptoms had elevated levels of CRP levels
compared to those who did not report symptoms of anxiety.
However, their findings were not affected by adjustment for a
range of covariates including BMI, whereas our results
became non-significant after adjusting for markers of an
unhealthy lifestyle behaviors (smoking, alcohol intake,
BMI, and physical inactivity), with BMI having the strongest
effect on the association. Furthermore, similar to our find-
ings, they did not find support for this association in women.
In contrast, Pitsavos et al. (2006) found significant associa-
tions for anxiety and inflammation in women. Interestingly,
the results published by Liukkonen and colleagues and Pitsa-
vos and colleagues did not diminish after adjustment for
markers of an unhealthy lifestyle behaviors as our results
did. Previous research has shown a positive relationship
between BMI and inflammation on one hand (Ferrante,
2007; Samaan, 2011) and BMI and anxiety on the other hand
(Roberts et al., 2007). One possible explanation could be that
our sample partly consists of psychiatric patients, in contrast
to the healthy samples used by Pitsavos et al. and Liukkonen
et al. Around 27% of the participants are recruited in spe-
cialized mental health care. It could be that this group of
participants has more adverse markers of an unhealthy life-
style behaviors contributing to inflammation and/or anxiety
compared to healthy participants. Furthermore, our results
suggest that also the anxiety-inflammation relationship is
mainly driven by somatic symptoms. Somatic symptoms of
anxiety consist of hot flushes, respiration, heart pounding,
shaking hands and difficulty breathing. This sheds a new light
on anxiety and inflammation. In contrast to somatic symp-
toms of depression, somatic symptoms of anxiety are not
similar to symptoms of sickness behavior, but may be seen as
a reflection of autonomic control, suggesting a role for the
autonomic nervous system (ANS). The ANS is also associated
with higher levels of inflammation (Haensel et al., 2008;
Miller et al., 2009; Haarala et al., 2011) and could possibly be
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examining anxiety and the ANS show conflicting results
(Friedman, 2007; Licht et al., 2009, 2010) as to whether
the ANS and anxiety are associated. Possibly, the ANS is only
involved in the somatic symptoms of anxiety and affects
immune function simultaneously.
This study is conducted on cross-sectional data, imply-
ing that no inferences can be made on the direction of the
relationship of depression and anxiety with inflammation.
There is some evidence that suggests that depressive
symptoms are associated with subsequent inflammation
(Hamer et al., 2009; Stewart et al., 2009; Duivis et al.,
2011; Copeland et al., 2012), but the opposite has been
reported as well (Gimeno et al., 2009). Regarding anxiety
there is little evidence on the direction of the association,
though it has been suggested that pro-inflammatory cyto-
kines rise in the presence of anxiety, due to chronic stress
(O’Donovan et al., 2010). Up to date there is no long-
itudinal research conducted which could provide insight
into the direction of the anxiety-inflammation relationship
and into a more thorough understanding of mechanisms
involved in this relationship.
Another limitation is that this is a secondary data-analysis
using inflammatory markers. Finally, we assessed circulating
levels of inflammatory markers, which show a high degree of
intra-individual variation. This could explain why we found
the rather modest associations between symptoms of depres-
sion and anxiety with inflammatory marker levels in our
study.
Some strengths can be attributed to our study, such as a
large sample size with a wide range on psychopathology
thereby increasing the power of our analyses, which made
it possible to adequately adjust for potential confounders. In
addition, multiple inflammatory markers were assessed.
In conclusion, our results suggest an association between
depressive and anxiety symptoms with inflammation, in
which associations were mainly driven by the somatic symp-
tom components. Nevertheless, adjustment for markers of an
unhealthy lifestyle factors diminished all associations to non-
significance indicating that it is the poorer lifestyle of
depressed and anxious patients that puts them at risk for
inflammation.
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